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Abstract
Background: Activation of indoleamine 2,3-dioxygenase (IDO) and higher concentrations of several kynurenine
metabolites have been observed post-stroke, where they have been associated with increased mortality. While
lower tryptophan or a higher ratio of kynurenine/tryptophan (K/T) in peripheral blood have been associated with
dementia and the severity of cognitive symptoms in Alzheimer’s disease, the association between K/T ratios and
post-stroke cognitive impairment (PSCI) has not been investigated.
Methods: Patients were recruited from the acute stroke unit of a general hospital within 1 month post-stroke.
Assessments included the Standardized Mini-Mental State Examination (sMMSE) for cognition, the National
Institutes of Health Stroke Scale (NIHSS) for stroke severity, and the Center for Epidemiological Studies-Depression
Scale (CES-D) for depressive symptoms. Tryptophan and kynurenine concentrations were determined by high-
performance liquid chromatography.
Results: A total of 41 patients with ischemic stroke ([mean ± SD] age 72.3 ± 12.2 years, 53.7% male, sMMSE 25.6 ±
4.1, NIHSS 7.27 ± 5.55) were recruited. Higher K/T ratios were associated with lower post-stroke global cognition (i.
e. sMMSE scores; b = -.327, P = .037). A backward stepwise elimination linear regression (F1,40=6.15, P=.005,
adjusted R
2=.205) showed that the highest K/T ratio tertile (b = -.412, P = .006) predicted lower sMMSE scores,
controlling for age (b = -.253, p = .081), with NIHSS (b = -.027, P = 0.859), and lesion volume (b = -.066, P = 0.659)
removed from the model. In receiver operating characteristic analysis, a K/T ratio of 78.3 μmol/mmol (top tertile)
predicted significant cognitive impairment (sMMSE score ≤ 24) with 67% sensitivity and 86% specificity (area under
the curve = 0.730, p = .022).
Conclusions: These data suggest an inflammatory response characterized by IDO activation may be relevant to the
development of PSCI. Since the neuroactivity of kynurenine metabolites may be amenable to pharmacotherapeutic
intervention, the K/T ratio may be a clinically important biomarker.
Background
Stroke affects 15 million individuals annually world-wide,
and the risk of having a stroke more than doubles each
decade after the age of 55 [1]. Most stroke survivors live
with residual impairments that diminish independence
and quality of life [2]. For older patients with ischemic
stroke, post-stroke cognitive impairment (PSCI) is
particularly important and frequent, occurring in approxi-
mately one third of all patients [3] and having a significant
negative impact on rehabilitation outcomes [4], quality of
life [5] and risk of dementia [6]. A recent meta-analysis
has confirmed several risk factors, including previous
symptomatic stroke, previous asymptomatic stroke seen
on imaging, multiple stroke lesions, aphasia, stroke sever-
ity, and stroke location, are associated with PSCI as
defined by Mini-Mental State Examination (MMSE) scores
less than 24, Diagnostic and Statistical Manual of Mental
Disorders IV (DSM-IV) or International Classification of
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any medium, provided the original work is properly cited.Disease-10 (ICD-10) criteria, within 1 year after stroke [7].
The prevalence of post-stroke MMSE scores less than 24,
indicative of significant cognitive impairment, was much
higher than the prevalence of dementia diagnosed by stan-
dard criteria, which included the DSM-IV or ICD-10 [7].
The majority of these and other known risk factors for
PSCI including older age, lower level of education, family
history of dementia [8] are not readily amenable to treat-
ment. Therefore, there is considerable need to identify
pathophysiological mechanisms that may contribute to
PSCI.
The systemic inflammatory response to acute ischemic
stroke involves increases in several pro-inflammatory
cytokines and C-reactive protein (CRP) [9-11], which
have also been associated with the development of cog-
nitive deficits and dementia in aging populations [12].
We have recently demonstrated a relationship between
PSCI and two inflammatory biomarkers, CRP and inter-
leukin-6 (IL-6) [13]. Pro-inflammatory cytokines can
activate the indoleamine-2,3-dioxygenase (IDO) enzyme,
leading to the depletion of tryptophan (TRP) and the
production of kynurenine, increasing the kynurenine/
tryptophan (K/T) ratio in peripheral blood, which acts
as a clinical measure of IDO activity [14]. Elevations in
the K/T ratio and in the concentrations of several
kynurenine metabolites have been observed post-stroke,
where they have been associated with mortality [15].
While lower peripheral blood tryptophan concentrations
or higher K/T ratios have been associated with dementia
and the severity of cognitive symptoms in Alzheimer’s
disease [16,17], the association between K/T ratios and
PSCI has not been investigated.
Tryptophan metabolites along the kynurenine pathway
can produce excitatory and oxidative neurotoxicity, but
also protect neurons from inflammatory damage and
attenuate excitatory neurotoxicity via NMDA receptor
antagonism [18-23]. Therefore, it is of interest to deter-
mine whether kynurenine production might be asso-
ciated with clinical cognitive outcomes, and if so, at
which concentrations.
The purpose of this study was to test the hypothesis
that IDO activation is associated with the presence of
cognitive symptoms post-stroke. We measured plasma
concentrations of kynurenine and tryptophan in acute
ischemic stroke patients and explored the relationship
between the K/T ratio and cognitive deficits, as mea-
sured by the MMSE, a commonly used cognitive screen-
ing instrument [24].
Methods
Study design
This cross-sectional observational study recruited parti-
cipants admitted to an acute care regional stroke centre
within 30 days of an ischemic stroke. The study was
approved by local research ethics boards, and all partici-
pants provided written informed consent.
Recruitment
Consecutive patients meeting the National Institute of
Neurological and Communicative Disorders and Stroke
(NINCDS) [25] and World Health Organization Multi-
national Monitoring of Trends and Determinants in
Cardiovascular Disease (WHO - M O N I C A )[ 2 6 ]c r i t e r i a
for stroke were invited to participate in this study.
Acute ischemic infarcts were verified from computed
tomography (CT) or magnetic resonance imaging (MRI)
reports performed at the time of admission in all
patients. Inclusion criteria also required participants to
speak and understand English. Exclusion criteria were:
pre-stroke diagnosis of dementia or significant cognitive
impairment, primary hemorrhagic stroke (which have a
different etiology and clinical course), decreased level of
consciousness, severe aphasia or dysarthria (which
would interfere with the ability to complete the study
assessments), significant acute medical illness (which
would be associated with significant inflammatory bur-
den of its own; e.g. infection, autoimmune disease, can-
cer), significant acute neurological illness other than
stroke, and the presence of a premorbid axis I psychia-
tric disorder. A history of major depression was per-
mitted, and controlled for in statistical analyses as
needed.
Assessments
After obtaining written informed consent, the Mini-
Mental State Examination (MMSE) [24] was adminis-
tered. The MMSE was selected as a cognitive screening
instrument because it is a brief, widely used, and vali-
dated scale in acute care settings [27]. Although not
sensitive to subtle cognitive impairment, scores on the
MMSE correlate strongly with the more thorough yet
lengthy CAMCOG (cognitive and self-contained part of
the Cambridge Examination for Mental Disorders of the
Elderly) in a stroke rehabilitation setting [28]. Given the
exploratory nature of this study and the potentially low
tolerability of a longer assessment in an acute stroke set-
ting, a brief yet validated and clinically meaningful cog-
nitive instrument was selected. MMSE scores were
adjusted according to physical ability post-stroke as
recommended by the Standardized Mini Mental State
Examination (sMMSE) [29].
Stroke severity was assessed using the National Insti-
tutes of Health Stroke Scale (NIHSS) [30], either as
completed by clinicians at the time of patient admission
and obtained through chart review, or extracted from
the chart information using a standardized method as
has been done before [31]. Depressive symptoms were
assessed using the Center for Epidemiological Studies-
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demographic characteristics and medical history was
collected via chart review and consultation with
participants.
Blood sampling and plasma analyses
Fasting blood was collected via venipuncture in EDTA
(ethylenediaminetetraacetic acid) BD Vacutainer
® (New
Jersey, USA) tubes at 7:30 am ± 30 minutes on the
morning after the clinical assessments were conducted.
Blood samples were centrifuged at 1000 × g for 10 min
at 4°C and plasma was separated and stored at -80°C
until the time of assay. Tryptophan and kynurenine con-
centrations were determined by high-performance liquid
chromatography (HPLC), as described elsewhere [33,34].
Tryptophan was measured by isocratic reverse phase
HPLC without derivatization and fluorescence detection.
For kynurenine, an equal volume of 3% perchloric acid
was used for protein precipitation. After centrifugation,
the concentration of L-kynurenine in the supernatant
was measured by HPLC with UV detection at 258 nm.
The mobile phase consisted of 9% acetonitrile in 0.05 M
potassium phosphate mono basic, pumped through a
reverse phase 5 μm ODS column, 250 mm × 4.6 mm
(Symmetry; Waters Corporation, Milford, Massachu-
setts, United States of America). Biochemical assays
were performed blinded to all clinical information.
Lesion characteristics were determined from CT scans
obtained without a contrast agent on a General Electric
LightSpeed VCT series scanner (General Electric
Healthcare, Waukesha, WI). Ischemic lesions were
manually traced on these images using Medical Image
Processing, Analysis, and Visualization (MIPAV;
National Institutes of Health, Bethesda, MD). Stroke
volume was calculated using a slice-by-slice planimetric
methodology employing these manual lesion tracings.
Statistical Analysis
Continuous measures were summarized using means
and standard deviations whereas categorical measures
were summarized using percentages. Tryptophan and
kynurenine were determined by mass and converted to
molar units. Their quotient was multiplied by 1000 to
obtain the K/T ratio in units of μmol/mmol. The natu-
rally skewed nature of the data resulted in absolute
values of kurtosis and skewedness being greater than 2
SD of the error, so K/T values were log transformed to
obtain a normal distribution. All statistical analyses were
performed using transformed values or tertiles.
For initial descriptive analyses, the relationship
between sMMSE scores and K/T ratio, as well as possi-
ble covariates such as age, gender, stroke severity, time
since stroke, level of education, cumulative burden of
cerebrovascular risk factors (i.e. the number of vascular
risk factors including diabetes, smoking, hypertension,
hyperlipidemia, and obesity summed), and lesion volume
were analyzed with bivariate Pearson correlations or
analyses of variance (ANOVA) as appropriate.
To test our hypothesis, a backward elimination multi-
ple linear regression model was used to examine the
association between K/T ratios and sMMSE scores as
continuous variables with age, stroke severity, and lesion
volume entered into the initial model. In addition, to
determine if an elevated K/T ratio predicted poorer
sMMSE scores, patients were divided into tertiles based
on the K/T ratio, and a backward elimination multiple
linear regression analysis with patients dichotomized by
those in the top tertile vs. others was used. A removal
criterion of P > .1 was used in backward regression
models. Finally, a receiver operating characteristic
(ROC) analysis was performed to determine a K/T ratio
optimum (sensitivity vs. specificity) that predicts signifi-
cant cognitive impairment (sMMSE score ≤24) [7].
Given the strong commonly observed relationships
between depressive symptoms, inflammatory activation
[35] and cognitive impairment [36,37], the impact of
depressive symptoms or a history of depression on the
observed relationship between K/T ratio top tertile and
sMMSE was explored by adding CES-D scores or his-
tory of depression into the final regression model. Simi-
larly, given the observed relationship between vascular
risk factors and cognitive impairment [38], the number
of cerebrovascular risk factors was added to the final
regression model. Time since stroke, gender, and level
of education were also explored as covariates.
All patient information was de-identified for statistical
analyses using SPSS statistical software (version 17;
SPSS Inc., Chicago, Illinois).
Sample size and study power calculation
A sample size of 39 subjects achieves a power of 80% to
detect an association between the K/T ratio and
sMMSE scores with an effect size (f
2)o f0 . 3 5g i v e na
two-tailed significance level of 0.05. A sample size of at
least 41 subjects allows adjustment with up to 3 addi-
tional covariates.
Results
A total of 41 patients (mean ± SD age 72.3 ± 12.2 years,
53.7% male) were recruited. Tryptophan and kynurenine
chromatograms appeared as previously described [33].
The mean K/T ratio was 67.40 ± 42.46 μmol/mmol.
Scores on the sMMSE ranged from 13 to 30, with 29.3%
of the sample having evidence of significant cognitive
impairment (sMMSE ≤ 24). Table 1 reports the results
of correlations with sMMSE scores and K/T ratios, as
well as between sMMSE scores and demographic and
lesion characteristics. In addition to K/T ratio, time
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sMMSE scores, with a trend for age to be significantly
associated (Table 1). No association between lesion
volume and sMMSE scores was found.
The bivariate correlation between sMMSE scores and
the K/T ratio persisted (b = -.327, P = .037) in a backward
stepwise elimination linear regression where age, lesion
volume, and stroke severity were removed from the model
(adjusted R
2 = .084). When patients were dichotomized by
those in the highest K/T ratio tertile versus others, being
in the top tertile emerged as a significant predictor of
sMMSE scores (b = -.412, P = .006) when controlling for
age (b = -.253, P = .081) with stroke severity (b=-.027,
P=0.859) and lesion volume (b=-.066, P=0.659) removed
from the final model (adjusted R
2 = .205, F1,40 = 6.15, p =
.005; Table 2). When exploring gender, time since stroke,
level of education, number of cerebrovascular risk factors,
history of depression, or CES-D scores as covariates, the
association between the K/T ratio top tertile and sMMSE
scores remained significant (P < .018). A plot depicting the
relationship between the K/T tertiles and sMMSE scores
is provided in Figure 1.
In an ROC curve, a K/T ratio of 78.3 μmol/mmol pre-
dicted the presence of an sMMSE score ≤ 24 with 67%
sensitivity and 86% specificity (Figure 2). The area under
Table 1 Clinical characteristics and correlations with cognitive impairment (n = 41)
MEAN ± SD OR % RANGE r- OR F* VALUE P-VALUE
†
Age 72.3 ± 12.2 years 39-91 years -0.27 0.08
Gender 53.7% male 1.83 0.18
MMSE 25.6 ± 4.1 13-30 - -
NIHSS 7.27 ± 5.55 0-21 -0.08 0.63
CES-D 13.8 ± 12.8 0-48 -0.09 0.59
History of Depression 7.3% 0.35 0.56
Living Alone 24.4% 0.06 0.81
Level of Education > high school 46.3% 6.64 0.01
Time Since Stroke 9.17 ± 5.03 days 4-26 days -0.34 0.03
Cerebrovascular Risk Factors
Hypertension 85.4% 4.53 0.04
Diabetes 26.8% 0.21 0.65
Hyperlipidemia 34.1% 0.41 0.52
Obesity (BMI ≥ 30kg/m
2) 31.7% 2.17 0.15
Smoking 22.0% 0.10 0.75
Total number risk factors 2.15 ± 1.28 0-5 -0.21 0.19
Lesion Volume (cm
3) 31.72 ± 55.09 0.250 -287.58 -0.05 0.76
K/T ratio
‡ 67.40 ± 42.46 14.04-203.75 -0.33 0.04
Abbreviations: MMSE, Mini-Mental State Examination; NIHSS, National Institutes of Health Stroke Scale; CES-D, Center for Epidemiological Studies-Depression
Scale; BMI, body mass index; K/T ratio, Kynurenine/Tryptophan ratio.
*r or F values and their corresponding
†p-values reflect the results of bivariate Pearson correlations with sMMSE scores for continuous variables and ANOVA
between sMMSE scores -for categorical variables;
‡ values reflect the mean ± SD of the detectable samples in each group.
Table 2 Linear regression model predicting sMMSE
scores*
B Std. Error b P
K/T top tertile -3.61 1.28 -.410 .008*
NIHSS -.020 .111 -.027 .859
Age -.085 .049 -.254 .088
Lesion Volume -4.95E-6 .000 -.066 .659
*Starting block with all covariates entered (overall adjusted R
2 = .167, F1, 40 =
3.01, p = .031). After backward elimination (p > .1), K/T ratio top tertile (b =
-.412, p = .006) and age (b = -.253, P = .081) remained in the model (overall
F1, 40 = 6.15, p = .005, adjusted R
2 = .205).
Figure 1 Box and whisker plot representing the relationship
between standadized Mini-Mental State Examination (sMMSE)
scores and K/T tertiles, represented as low (mean ± SD = 29.07
± 7.31), middle (mean ± SD = 58.39 ± 10.86), high (mean ± SD
= 116.12 ± 39.44). The black horizontal line in each box represents
the median. Outliers (circles) are recorded individually.
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will have a K/T ratio that correctly ranks their likelihood
of having an sMMSE score ≤ 24.
Discussion
This study demonstrates an association between elevated
K/T ratios and the extent of cognitive impairment
among acute ischemic stroke patients. Age, stroke sever-
ity and lesion volume did not significantly modify this
relationship suggesting that the clinical importance of
the K/T ratio may extend beyond their relationships
with these established risk factors for PSCI. The associa-
tion between the K/T ratio and cognition following
acute stroke was sufficiently robust to be detected with
the MMSE, a practical and clinically meaningful cogni-
tive screening instrument.
Inflammatory activation is a key process in the
ischemic cascade that leads to secondary brain damage
[39]. We have previously reported that plasma CRP con-
centrations were able to explain 20% of the variance in
MMSE scores among acute stroke patients and that
plasma IL-6 concentrations also predicted MMSE scores
[13]. Interestingly, high plasma concentrations of the
pleiotrophic cytokine, IL-6, have been associated with a
greater lesion volume [40], however lesion volume did
not predict sMMSE scores in our population. Pro-
inflammatory cytokines induce the expression of IDO
which catalyzes the committal and rate-limiting step in
the production of kynurenine from tryptophan. In the
present study, having a K/T ratio in the top tertile
explained 21% of the variance in MMSE scores.
An elevated K/T ratio has been associated with
inflammatory and neurodegenerative conditions and
with clinically important outcomes, including mortality
in the very old [41], poorer cognitive function in those
with Alzheimer’s disease [17], and the severity of
depressive symptoms in those receiving interferon ther-
apy [42] or in those with cardiovascular disease [43].
The K/T ratio and poorer MMSE scores may be related
to the burden of neurotoxic or neuroactive metabolites
such as quinolinic acid (QUIN), an NMDA receptor
agonist and excitatory neurotoxin, 3-hydroxyanthranilic
acid, an oxidative neurotoxin, or kynurenic acid
(KYNA), an antagonist at both NMDA and a7 choliner-
gic receptors. The production of these neuroactive
metabolites has been previously associated with depres-
sion [44,45], cognitive impairment, and deficits in learn-
ing, retrieval, and long-term memory [40,46]. For
instance, the concentration of KYNA is elevated in the
caudate nucleus and putamen of Alzheimer disease
patients [47] and it has been suggested that NMDA or
a7 cholinergic inhibition by KYNA might impair learn-
ing and memory [48]. In a study by Widner et al., Alz-
heimer’s disease patients showed significantly higher
peripheral blood K/T ratios as compared to age-
matched controls and Alzheimer’s disease patients with
the lowest MMSE scores had significantly higher K/T
ratios than those with the highest MMSE scores [17]. A
second study by Gulaj et al. did not find a correlation
between K/T ratios and MMSE scores; however they
observed an association between the KYNA/KYN ratio
and MMSE scores, suggesting a possible protective
effect of KYNA relative to the production of kynurenine
and other metabolites [16]. This effect may be attributa-
ble to opposing effects of KYNA and quinolinic acid at
NMDA or a7 nicotinic cholinergic receptors. The asso-
ciation between increased concentrations of kynurenine
metabolites, especially KYNA and 3-hydroxyanthranilic
acid, and mortality observed post-stroke [15] suggests
the potential clinical importance of these metabolites in
this population.
Identification of the K/T ratio as a PSCI biomarker
may represent an important step in improving stroke
outcomes because the kynurenine metabolites might be
amenable to pharmacological manipulation [23]. In the
central nervous system, kynurenine aminotransferase II,
expressed primarily in astrocytes, is responsible for
KYNA synthesis while kynurenine 3-monooxygenase
(KMO) produces the 3-hydroxykynurenine metabolite
that gives rise to QUIN, predominantly from the micro-
glia [49]. In animal models of cerebral ischemia, admin-
istration of kynurenine sulfate exerts neuroprotective
effects and notably increases cerebral concentrations of
KYNA [50,51]. It is now appreciated that cerebral 3-
hydroxykynurenine and quinolinic acid concentrations
can be manipulated, selectively without altering KYNA
concentrations, by inhibition of KMO [49], an approach
Figure 2 Optimal K/T to detect significant cognitive
impairment. Receiver Operating Characteristic Curve. A K/T ratio of
78.3 μmol/mmol predicted significant cognitive impairment (sMMSE
score ≤ 24) with 67% sensitivity and 86% specificity. Area under the
curve = .730[.548, .912]; Std Error = .093, p = .022.
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cerebral ischemia [19]. In addition, a newly synthesized
compound, ZL006, which acts downstream of NMDA
receptor activation, has been demonstrated to ameliorate
focal ischemic cerebral damage induced by middle cere-
bral artery occlusion in mice and rats [52]. The implica-
tion of endogenous excitotoxicity in the present study
suggests that ZL006 might also be evaluated to improve
cognitive outcomes.
In the present study, the K/T ratio was able to identify
subjects at risk of significant PSCI (i.e. those with
sMMSE scores ≤ 24). While larger studies would be
needed to confirm a clinically important cut-off value
for the K/T ratio, the ROC presented in the present
study suggested a 67% sensitivity and 86% specificity for
a K/T ratio cut-off of 78.3 μM/mM. While higher K/T
ratios were associated with lower MMSE scores in the
entire population, this effect was most significant for
subjects with a K/T ratio in the highest tertile. A K/T
ratio in this range is comparable to that found in sub-
jects with HIV-1 infection in association with cognitive
symptoms and AIDS dementia complex [53-55], but
much higher than that found in normal healthy aged
controls [15] or subjects with cardiovascular disease
without a history of stroke [43]. If replicated in larger
populations, these data suggest potential clinical utility
of the K/T ratio as a discriminating biomarker.
This study demonstrates a relationship between cogni-
tive impairment and activation of the kynurenine path-
way post-stroke. It is, however, limited by its use of a
brief cognitive screening instrument and a relatively
small sample size. Although stroke severity was assessed
and included as a covariate, the timing of administration
of the NIHSS relative to the stroke and cognitive assess-
ment varied between assessments. Because NIHSS scores
commonly fluctuate post-stroke, this measure may not
have been adequate to control for stroke severity. How-
ever, in recognition of this, we also evaluated lesion
volume and found that it was not significantly related to
the severity of PSCI in this population. Additionally, the
type of cognitive impairment observed post-stroke varies;
often including deficits in measures of global cognition,
as well as domain-specific impairments involving execu-
tive function, language, visuospatial ability, and memory
[56]. Some previously identified risk factors for the devel-
opment of PSCI, including family history of dementia
and individual cardiovascular risk factors [8], could not
be controlled for given the sample size. Although all
efforts were made to control for potentially confounding
variables, pre-stroke cognitive capacity and white matter
disease burden were not assessed. Finally, the cross-sec-
tional design of this study was useful in establishing an
initial relationship between PSCI and elevated K/T ratios
post-stroke, but subsequent longitudinal studies will be
necessary to determine the value of K/T ratio in predict-
ing long-term cognitive outcomes.
Conclusions
In summary, an acute inflammatory response character-
ized by IDO activation may be relevant to the develop-
ment of PSCI. Since the neuroactivities of kynurenine
metabolites may be amenable to pharmacotherapeutic
intervention, the K/T ratio may be a clinically important
biomarker. Longitudinal observational and intervention
studies will improve our understanding of the role of
IDO activity in PSCI.
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